Vitamin E intake reduces plasminogen activator inhibitor type 1 in T2DM patients

A. R. Bonfigli, C. Pieri, S. Manfrini, I. Testa, C. Sirolla, R. Ricciotti, M. Marra, P. Compagnucci, R. Testa

Research output: Contribution to journalArticlepeer-review


Previous studies hypothesised that vitamin E could protect against coronary heart disease and vascular complications in diabetes, but no studies have been performed regarding its eventual effects on fibrinolysis. Nevertheless, in Type 2 diabetes mellitus (T2DM) a profound reduction in the fibrinolytic activity has been demonstrated to be involved in vascular complications, probably due to plasminogen activator inhibitor type 1 (PAI-1) overproduction. On this basis we aimed to verify whether an antioxidant treatment with vitamin E is able to lower PAI-1 plasma levels in T2DM. Thirteen T2DM patients (9 males and 4 females; mean age±SD, 64.4±3.3 yr) were selected through strict admission criteria. These patients were treated with vitamin E (500 IU/die) for 10 weeks. Glyco-lipometabolic, oxidative and haemocoagulative parameters were evaluated at baseline and after 5, 10, 30 and 60 weeks. Vitamin E levels at different times were [median (interquartile range)] 6.1 (5.3-7.7), 8.5 (7.3-9.9), 9.7 (8.9-12.9), 5.6 (4.4-6.8), 5.7 (4.5-7.1) μg/ml, respectively. Significant differences were found for PAI-1 antigen (p=0.006), PAI-1 activity (p=0.028), apolipoprotein B (p=0.015) and antioxidant defence, evaluated as ferric reducing ability of plasma (FRAP) values (p=0.005). Particularly, decrements were detected for PAI-1 antigen between baseline and the 10th week (p

Original languageEnglish
Pages (from-to)71-77
Number of pages7
JournalDiabetes, Nutrition and Metabolism - Clinical and Experimental
Issue number2
Publication statusPublished - 2001


  • PAI-1
  • Type 2 diabetes mellitus
  • Vitamin E.

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Internal Medicine
  • Endocrinology
  • Food Science
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'Vitamin E intake reduces plasminogen activator inhibitor type 1 in T2DM patients'. Together they form a unique fingerprint.

Cite this